Center for Addiction Science, Policy, and Research

Our mission is to solve addiction at a population level.

We pursue high leverage research and policy strategies to advance breakthrough medications for substance use disorders. Follow our work at: Recursive Adaptation.

Our pilot programs, the only two in the world providing GLP-1s to addiction patients, have received coverage in the New York Times and STAT, and many other publications.

CASPR PROGRAMS

NOVEMBER 2025

Washington Post coverage of CASPR's GLP-1 pilot programs

Washington Post covers both of CASPR's GLP-1 pilot programs

Coverage of our programs at Caron and OpenDoors reaches DC policymakers.

OCTOBER 2025

New York Times coverage of GLP-1s for addiction

New York Times covers our pilot program with Open Doors

GLP-1s for women in post-incarceration housing.

AUGUST 2025

FDA National Priority Vouchers

FDA's new National Priority Vouchers could grow the addiction medicine pipeline

A policy win that could accelerate drug approvals by 10 months.

JULY 2025

Dr. Steve Klein - STAT coverage of Caron Center GLP-1 program

STAT Coverage of Our Pilot Program at Caron Centers

Providing GLP-1s to inpatients with Dr. Steve Klein.

APRIL 2025

What CASPR has been working on

Updates on CASPR's Core Programs

Trials and projects that CASPR is running or making possible.

APRIL 2025

GLP-1s for Reducing Addiction

GLP-1s for Reducing Addiction

Research and experiences from doctors and patients.

JANUARY 2025

Podcast episode with Chris Hayes

Podcast episode with Chris Hayes

Executive Director Nicholas Reville on addiction medicine, GLP-1s, and innovation policy.

NOVEMBER 2024

VA study on GLP-1s and opioid use in veterans

VA study on GLP-1s and opioid use in veterans

Our first collaboration with the Department of Veterans Affairs.

SEPTEMBER 2024

Addiction medicine doctors who use GLP-1s

Addiction medicine doctors who use GLP-1s

"I'm now offering GLP-1s to nearly all my substance use disorder patients."

JULY 2024

GRACE for Opioid Use Disorder

GRACE for Opioid Use Disorder

A novel GLP-1 based harm reduction strategy.